Nicholas T. Crump

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells.

Inhibition of MLLT1 Limits Growth of KMT2A::AFF1 Leukemias Without Killing Healthy Hematopoietic Stem Cells.

Journal: Experimental hematology
Published: April 16, 2026

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

Journal: Blood
Published: February 04, 2026

mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.

mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.

Journal: Leukemia
Published: October 31, 2025

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 05, 2025

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.

BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 05, 2025

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Journal: Blood
Published: June 17, 2025

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Journal: Blood
Published: June 17, 2025

EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.

EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway.

Journal: Haematologica
Published: April 12, 2025

Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.

Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients.

Journal: Blood
Published: December 13, 2024

PROM1/CD133 marks a proliferative stem cell-like population of blasts in KMT2A rearranged infant ALL.

PROM1/CD133 marks a proliferative stem cell-like population of blasts in KMT2A rearranged infant ALL.

Journal: Blood advances
Published: October 29, 2024

Is Enhancer Function Driven by Protein-Protein Interactions? From Bacteria to Leukemia.

Is Enhancer Function Driven by Protein-Protein Interactions? From Bacteria to Leukemia.

Journal: BioEssays : news and reviews in molecular, cellular and developmental biology
Published: July 07, 2024

Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation.

Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation.

Journal: Nature cardiovascular research
Published: March 19, 2024
Showing 1-12 of 25

Last Updated: 09/26/2026